Gateway Biotechnology

Science-based Solutions to Hearing Disorders

Learn More

About Us

73 Million

People in the US are living with NIHL and tinnitus

$ 1.3 Billion

Potential market for NIHL and tinnitus in the US

Zero

FDA-approved drugs for NIHL or tinnitus

We’re A Biotech R&D Company.

Over 1.5 billion people worldwide suffer from hearing disorders, including hearing loss due to aging (Age-related Hearing Loss, ARHL) or noise exposure (Noise-Induced Hearing Loss, NIHL). In the U.S. alone, hearing disorders affect 73 million Americans. The National Institute for Occupational Safety and Health estimates that each year over 22 million workers are exposed to damaging levels of noise and hearing loss is the most common work-related illness in the U.S. Currently, there are no drugs approved by the US Food and Drug Administration (FDA) on the market for hearing loss prevention or treatment of hearing loss.

With a decade of product development funded by initial investment from co-founders and subsequent awards from National Institutes of Health (NIH), Gateway Biotechnology has been developing drug candidates with proven safety records to combat hearing disorders. Our innovative approach, grounded in a deep understanding of basic mechanisms underlying hearing loss, targets multiple cellular pathways with new product formulations that fine-tune drug delivery to the ear.

image

Our Strategy

Drug Repurposing

Developing drug candidates with proven safety records make us time-efficient and cost-effective.

New Drug Development

Discovering new product formulations that fine-tune drug delivery to the ear.

Targeted Delivery

Researching new Adeno-Associated Virus (AAV)-based tools to target cells of the inner ear to fight against hearing loss.

New Detection Methods

Utilizing Artificial Intelligence (AI) technology to create innovative methods to detect early signs of hearing disorders.

Product Pipelines

Robust pipeline for science-based solutions to hearing disorders

We have developed animal model systems for pre-clinical trials of drug candidates and have advanced our leading drug candidate to a clinical Phase II trial with the US Army. NIH-supported research is now enabling us to move additional candidates through our discovery pipeline.

  • GW-101Prevent NIHL

  • GW-102Prevent & Treat NIHL

  • GW-103Treat NIHL

  • GW-201Treat Tinnitus

  • GW-301Prevent Cisplatin Ototoxity

2

Patents Filed

5

Papers Published

7

SBIR/STTR Grants Received

Our Team

Meghna

Dr. Bao started his independent research career in auditory neuroscience at Columbia University, and later became a tenured faculty at Washington University in St. Louis. With over 20 years of research experience in the field of hearing disorders, Dr. Bao’s research excellence has been recognized by multiple awards from National Institute on Aging and the National Institute on Deafness and Other Communication Disorders. His interactions with clinicians and researchers at both academic and industrial institutions led to the formation of Gateway Biotechnology Inc., which focuses on developing new products for hearing disorders.

Jianxin Bao, Ph.D.

CEO/Founder
Meghna

Dr. Chole is a well-known clinician with a specialty in neurotology, and he has also led multiple funded research projects in the Department of Otolaryngology at Washington University in St. Louis. Dr. Chole carried out the first study of age-related hearing loss in the C57BL/6J strain of mice. He has experience in clinical studies and has conducted several randomized clinical trials in the field of hearing disorders. Dr. Chole's clinical interests include otology, neurotology, reconstruction of the middle ear, petrous apicitis, otosclerosis, cholesteatoma, Meniere's disease, cochlear implants and bone-anchored hearing aids.

Richard Chole, M.D., Ph.D

Co-founder
Meghna

Dr. Perez received his undergraduate education at Harvard University, and his medical school education at Washington University in St. Louis. He has been involved in the first drug repurposing studies against hearing loss at Washington University in St. Louis. He is now practicing at the Department of Otolaryngology-Head and Neck Surgery at the University of California in San Francisco.

Philip Perez, M.D.

CMO/Co-founder

Latest Posts

post-image

Hidden hearing loss & hearing therapies featured at Association for Research in Otolaryngology

Every year, scientists who conduct research in otolaryngology (the biomedical science that focuses on the ears, nose, and throat) come together and share with one another their latest and most exciting research discoveries at the Midwinter Meeting of the Association for Research in Otolaryngology (ARO). This year, the event (held February 9-14 in sunny San Diego) offered hours of scheduled events and symposia on some of the hottest topics in the field.

Read more
post-image

Debunking eight myths about hearing loss

Thirty years ago, few people could have told you what an audiologist is…or does…but today, things are different. Most of us know that an audiologist is a person who tests hearing and fits hearing aids. But beyond that, our knowledge of hearing and hearing loss is sometimes distorted, outdated, or just plain wrong. So, let’s take a look at some of the most common misconceptions and sort out the truth.

Read more
post-image

Noise: The not-so-silent Health Hazard

We’ve all heard about the silent killers—health hazards such as stress and hypertension that can wield their dangerous effects by sneaking up on us, without our realizing it. But scientists are also finding that a lifetime of everyday noise levels can be just as dangerous, not just to our hearing health, but to our stress levels, sleeping ability, and cardiovascular health. The noise levels we’re talking about extend beyond those we’re already well aware of—those produced by excessively loud gadgets or machinery that are damaging to structures in our inner ear.

Read more
View All Posts

Get In Touch

Contact Details

We are actively seeking partnerships and investment opportunities. Send us a message if you are interested!

1154 North Warson Road, St. Louis, MO 63132
Phone: +1 (781)609 8784
Email: aqiu@gatewaybiotechnology.com